Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients

Next Previous
X
Search
Trial Profile

A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crizanlizumab (Primary) ; Nisevokitug (Primary) ; Rineterkib (Primary) ; Ruxolitinib (Primary) ; Sabatolimab (Primary) ; Siremadlin (Primary)
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ADORE
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 19 Sep 2024 Status changed from active, no longer recruiting to completed.
    • 13 Sep 2024 This study has been Completed in Belgium.
    • 02 Aug 2024 Planned End Date changed from 31 Jul 2024 to 28 Aug 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top